Skip to content

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH

Jihye Yun, Edouard Mullarky, Changyuan Lu, Kaitlyn N. Bosch, Adam R. Kavalier, Keith D. Rivera, Jatin Roper, Iok In Christine Chio, Ευγενία Γιαννοπούλου, Carlo Rago, Ashlesha Muley, John M. Asara, Jihye Paik, Olivier Elemento, Zhengming Chen, Darryl Pappin, Lukas E. Dow, Nickolas Papadopoulos, Steven S. Gross, Lewis C. Cantley

Science · 2015 · 925 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A. R., Rivera, K. D., Roper, J., Chio, I. I. C., Γιαννοπούλου Ε., Rago, C., Muley, A., Asara, J. M., Paik, J., Elemento, O., Chen, Z., Pappin, D., Dow, L. E., Papadopoulos, N., Gross, S. S., & Cantley, L. C. (2015). Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science, 350(6266), 1391–1396. https://doi.org/10.1126/science.aaa5004

In text: (Yun et al., 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

More than half of human colorectal cancers (CRCs) carry either KRAS or BRAF mutations and are often refractory to approved targeted therapies. We found that cultured human CRC cells harboring KRAS or BRAF mutations are selectively killed when exposed to high levels of vitamin C. This effect is due to increased uptake of the oxidized form of vitamin C, dehydroascorbate (DHA), via the GLUT1 glucose transporter. Increased DHA uptake causes oxidative stress as intracellular DHA is reduced to vitamin C, depleting glutathione. Thus, reactive oxygen species accumulate and inactivate glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Inhibition of GAPDH in highly glycolytic KRAS or BRAF mutant cells leads to an energetic crisis and cell death not seen in KRAS and BRAF wild-type cells. High-dose vitamin C impairs tumor growth in Apc/Kras(G12D) mutant mice. These results provide a mechanistic rationale for exploring the therapeutic use of vitamin C for CRCs with KRAS or BRAF mutations.

  1. Sorafenib in Advanced Hepatocellular Carcinoma2008
  2. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer2004
  3. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency2015
  4. Comprehensive molecular characterization of human colon and rectal cancer2012
  5. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020

Metadata from OpenAlex (CC0). Citations are generated from the published record.